Brokerages forecast that KemPharm, Inc. (NASDAQ:KMPH) will announce $12.10 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for KemPharm’s earnings. The highest sales estimate is $12.20 million and the lowest is $12.00 million. KemPharm reported sales of $6.91 million during the same quarter last year, which indicates a positive year over year growth rate of 75.1%. The firm is expected to announce its next earnings report on Wednesday, August 11th.
According to Zacks, analysts expect that KemPharm will report full year sales of $28.67 million for the current financial year, with estimates ranging from $28.61 million to $28.72 million. For the next financial year, analysts forecast that the business will post sales of $31.75 million, with estimates ranging from $21.06 million to $42.45 million. Zacks’ sales calculations are an average based on a survey of research firms that follow KemPharm.
KemPharm (NASDAQ:KMPH) last released its quarterly earnings data on Thursday, May 13th. The specialty pharmaceutical company reported ($1.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($1.44). The business had revenue of $12.12 million during the quarter, compared to analysts’ expectations of $2.10 million.
In other KemPharm news, major shareholder Samuel J. Braun acquired 10,000 shares of the business’s stock in a transaction on Thursday, May 13th. The stock was purchased at an average price of $8.55 per share, for a total transaction of $85,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders acquired 10,225 shares of company stock valued at $88,036 in the last quarter. 1.30% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of the business. Millennium Management LLC acquired a new stake in KemPharm in the first quarter valued at $1,956,000. Geode Capital Management LLC acquired a new stake in KemPharm in the first quarter valued at $1,637,000. BlackRock Inc. acquired a new stake in KemPharm in the first quarter valued at $542,000. Arete Wealth Advisors LLC acquired a new stake in KemPharm in the first quarter valued at $486,000. Finally, Virtu Financial LLC acquired a new stake in KemPharm in the first quarter valued at $351,000. 8.23% of the stock is currently owned by institutional investors.
KemPharm Company Profile
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.
Recommended Story: What kind of dividend yield to CEF’s pay?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.